Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines

Non-covalent glycosylated gold nanoparticles/peptides nanovaccine has been firstly developed via β-cyclodextrin (β-CD) based host-guest assembled and indicated great potential for cancer therapy. [Display omitted] Herein, we firstly developed a non-covalent glycosylated gold nanoparticles/peptides nanovaccine which is assembled by β-cyclodextrin (β-CD) based host-guest recognitions. This nanovaccine can generate significant titers of antibodies and improve the therapeutic effect against melanoma, suggesting the immunogenicity of peptide antigens can be improved by loading with this carrier. The novel vaccine carrier provides a platform for the transport of various antigens especially T cell-independent antigens.